Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
ICU Medical, Inc. (ICUI) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ICU Medical, Inc. (ICUI) - $25 value - yours FREE >>
Image: Bigstock
Bruker Well Poised on Product Innovation amid Currency Woes
On Jun 14, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR - Free Report) − a global manufacturer of high-end analytical instruments used within the academic & government, pharma/biotech, clinical diagnostic and industrial markets. The company currently carries a Zacks Rank #3 (Hold).
Bruker started 2016 on a promising note, with its first-quarter results beating the Zacks Consensus Estimate on both fronts. A strong year-over-year revenue upside was driven by the company’s enhanced operating performance and significant bottom-line improvement.
During the reported quarter, Bruker expanded its existing MALDI Biotyper workflow’s menu to include selected high-value resistance testing for clinical microbiology research. The company also launched MBT Biotargets and introduced new research use-only capabilities to the MALDI Biotyper product portfolio.
Further, other products that the company recently launched include the honey profiling module of the NMR FoodScreener solution and the latest version of NMR wine screener module. Together these products are expected to contribute significantly to Bruker’s revenues.
On the flip side, unfavorable currency translation continues to be a major dampener for the stock. Evidently, changes in foreign exchange rates impacted Bruker’s revenues by 0.9% in the first quarter of 2016. For 2016, management expects revenues to face a 1.6% reduction owing to unfavorable currency.
Moreover, widespread macroeconomic uncertainties prevailing in countries like the U.S., Russia and certain European nations in which Bruker operates might hamper its revenue growth significantly, in case of any further economic downturn. Competitive headwinds also continue to pose threats to the stock.
Key Picks in the Sector
Better-ranked medical stocks are ICU Medical, Inc. (ICUI - Free Report) , LeMaitre Vascular, Inc. (LMAT - Free Report) and NuVasive, Inc. . All the three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>